Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.
You may also be interested in...
Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.
Ireland is developing a new policy intended to increase the use of biosimilars, taking account of initiatives in other countries. The government says the aim is to help boost competition and access to cheaper biologicals.